{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:41:10Z","timestamp":1782772870883,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate clinical and economic outcomes associated with the use of isavuconazole as antifungal prophylaxis in high\u2010risk immunocompromised patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients\/Methods<\/jats:title><jats:p>Retrospective, single\u2010centre cohort study of patients who received isavuconazole prophylaxis. Outcomes assessed included breakthrough <jats:styled-content style=\"fixed-case\">IFI<\/jats:styled-content>, early discontinuation of isavuconazole for any reason and antifungal prophylaxis prescribed at discharge. The impact on inpatient drug expenditure was evaluated using current isavuconazole and posaconazole drug costs per observed isavuconazole days of therapy (<jats:styled-content style=\"fixed-case\">DOT<\/jats:styled-content>) during the study period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred thirty\u2010eight courses of isavuconazole prophylaxis were administered to 98 inpatients (2193 <jats:styled-content style=\"fixed-case\">DOT<\/jats:styled-content>). Relapsed\/refractory acute myelogenous leukaemia was the indication for prophylaxis in over half (59.4%) of patients. Breakthrough <jats:styled-content style=\"fixed-case\">IFI<\/jats:styled-content> occurred in 8 (5.8%) courses. Suspected drug\u2010related toxicities led to early discontinuation in 6 (4.3%) courses (five hepatotoxicity, one drug rash). At discharge, 24 (17.4%) courses lacked insurance coverage for isavuconazole. The formulary switch to isavuconazole prophylaxis resulted in an estimated mean drug cost savings of $128.25 per <jats:styled-content style=\"fixed-case\">DOT<\/jats:styled-content> relative to estimated posaconazole costs (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Isavuconazole may be an option for antifungal prophylaxis in high\u2010risk immunocompromised adults and has the potential to produce significant inpatient drug cost savings. Further studies are needed to confirm the clinical efficacy and cost\u2010effectiveness of isavuconazole in this role.<\/jats:p><\/jats:sec>","DOI":"10.1111\/myc.12924","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T13:15:03Z","timestamp":1556889303000},"page":"665-672","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0069-4594","authenticated-orcid":false,"given":"Christina D.","family":"Bowen","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services Oregon Health &amp; Science University Hospital and Clinics Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2965-1355","authenticated-orcid":false,"given":"Gregory B.","family":"Tallman","sequence":"additional","affiliation":[{"name":"College of Pharmacy Oregon State University\/Oregon Health &amp; Science University Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Hakki","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Oregon Health &amp; Science University Hospital and Clinics Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Lewis \u2161","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services Oregon Health &amp; Science University Hospital and Clinics Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073"},{"key":"e_1_2_7_3_1","unstructured":"National Comprehensive Cancer Network.Prevention and Treatment of Cancer\u2010Related Infections (Version 1.2018)[Internet].2017Dec p. 1\u2013158. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf. 10 October 2018."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_2_7_6_1","volume-title":"Cresemba (isavuconazonium sulfate) [package insert]","year":"2015"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04569-14"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00863-13"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt508"},{"key":"e_1_2_7_10_1","unstructured":"Noxafil (posaconazole)[package insert].Whitehouse Station NJ:Merck & Co. Inc.;2017."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.620"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12731"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.5.614"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12452"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.286-293.2006"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00893-18"},{"issue":"10","key":"e_1_2_7_17_1","first-page":"1621","article-title":"Breakthrough invasive mold infections in the hematology patient: current concepts and future directions","volume":"67","author":"Lionakis MS","year":"2018","journal-title":"Clin Infect Dis"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_7_19_1","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events v4.0.Washington DC.:US Department of Health and Human Services;2017Nov p. 1\u2013147. Report No.: NIH publication 09\u20107473."},{"key":"e_1_2_7_20_1","unstructured":"European Medicines Agency. EMA\/596950\/2015 \u2010Assessment report: Cresemba[Internet]. European Medicines Agency;2015p. 1\u2013162. Available from:https:\/\/www.ema.europa.eu\/documents\/assessment-report\/cresemba-epar-public-assessment-report_en.pdf. 10 October 2018."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.02.004"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01230-18"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00071-2"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02589-16"},{"key":"e_1_2_7_26_1","volume-title":"Isavuconazole prophylaxis among solid organ transplant recipients: effectiveness, tolerability and drug interaction with tacrolimus","author":"Nguyen MH","year":"2017"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy260"},{"issue":"10","key":"e_1_2_7_28_1","first-page":"1610","article-title":"Breakthrough fungal infections in patients with leukemia receiving isavuconazole","volume":"67","author":"Rausch CR","year":"2018","journal-title":"Clin Infect Dis"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00046-13"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214539825"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00389-16"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00970-17"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0600-1"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.1000460"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-017-0907-5"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1086\/420936"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/myc.12924","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T09:09:36Z","timestamp":1693991376000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/myc.12924"],"URL":"https:\/\/doi.org\/10.1111\/myc.12924","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]},"assertion":[{"value":"2018-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}